Related references
Note: Only part of the references are listed.Efficacy and safety of nivolumab for metastatic biliary tract cancer
Miaomiao Gou et al.
ONCOTARGETS AND THERAPY (2019)
ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC plus mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
Angela Lamarca et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Makoto Ueno et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer
Changqing Xie et al.
HEPATOLOGY (2019)
Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies
Julius Strauss et al.
CANCER RESEARCH (2019)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
661PUpdated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer
Y-J Bang et al.
ANNALS OF ONCOLOGY (2018)
625PDPembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study
M Ueno et al.
ANNALS OF ONCOLOGY (2018)
1463PUpdated results of M7824 (MSB0011359C): A bifunctional fusion protein targeting TGF-β and PD-L1, in second-line (2L) NSCLC
L Paz-Ares et al.
ANNALS OF ONCOLOGY (2018)
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with advanced solid tumors.
Yutaka Fujiwara et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle et al.
CANCER DISCOVERY (2017)
TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures
Anna Maria Lustri et al.
PLOS ONE (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression
Chiung-Kuei Huang et al.
CANCER LETTERS (2016)
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations
Lorena Marcano-Bonilla et al.
CHINESE CLINICAL ONCOLOGY (2016)
Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets
Randall F. Holcombe et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition
Masaru Miyazaki et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2015)
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Mohsen Naghavi et al.
LANCET (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies
Eric I. Marks et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2015)
TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma
Yijie Chen et al.
BIOLOGICAL RESEARCH (2015)
Second-line chemotherapy in advanced biliary cancer: a systematic review
A. Lamarca et al.
ANNALS OF ONCOLOGY (2014)
Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
B. Goeppert et al.
BRITISH JOURNAL OF CANCER (2013)
Targeting the TGFβ signalling pathway in disease
Rosemary J. Akhurst et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
T. Okusaka et al.
BRITISH JOURNAL OF CANCER (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Epidemiology of biliary tract cancers: an update
G. Randi et al.
ANNALS OF ONCOLOGY (2009)
Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-β1 by overexpression of cyclin D1
Y Zen et al.
LABORATORY INVESTIGATION (2005)
Share Paper
